News

This past week, we reached a milestone that is nothing short of extraordinary. Our very first patients received the Ocumetics Accommodating Intraocular Lens. Just one week later, they are recovering well—and importantly, no complications have been observed.I cannot overstate how meaningful this moment is. For years, we have poured our hearts, energy, and belief into

Today, Ocumetics has entered the history books. Nearly two decades of relentless innovation, bold ambition, and unwavering belief have led to this defining moment: the first-in-human implantation of the Ocumetics Lens.What many once thought impossible is now reality. This achievement is not the work of one person or one idea, but the result of years

Ocumetics Director and CEO, Dean Burns, covers key details of our upcoming first-in-human study and recently opened private placement financing. Topics will include:Final steps leading up to the first-in-human studyDetails on the now-open private placement investment opportunityLive Q&A session with Dean BurnsThanks to everyone who joined us for the Webinar. It was an amazing turnout,

Ocumetics Director and CEO, Dean Burns, walks us through relevant topics including:First-in-human study timingRemaining steps to first-in-human studyQ&A sessionThanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in the future!https://youtu.be/NmBiGLHMhFo

Today marks a defining moment in the history of Ocumetics—and in the future of vision restoration worldwide.It is with great pride and anticipation that I share we are now entering the final stages before our First-In-Human (FIH) clinical study for the Ocumetics Lens. This is more than a corporate milestone; it is the beginning of

Ocumetics Director and CEO, Dean Burns, walks through relevant topics including:1. Development Update on the Ocumetics IOL2. Remaining steps to first-in-human study3. Q&A session Thanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in

Dear Stakeholders,I want to take a moment to update you on our progress with the development of Ocumetics’ accommodative intraocular lens (AIOL), which will soon undergo its first-in-human (FIH) trials.As you know, we are committed to pioneering advanced ophthalmic technologies that will transform the way we treat cataracts and other vision conditions. In recent internal

Ocumetics Director and CEO, Dean Burns, walks through relevant topics including:Successful manufacture of the Ocumetics IOLRemaining steps to first-in-human studyQ&A sessionThanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in the future!https://youtu.be/U0GrNVtLNSc?si=lZYKlYUM2tH-KDjJ

Dear Shareholders, Partners, and Visionaries, I am thrilled to share a ground-breaking development from Ocumetics Technology Corp. that marks a monumental step forward in the world of vision enhancement. Today, I am pleased to announce the successful manufacture of our accommodating intraocular lens (IOL) designed to respond to the natural muscle activity of the human

Ocumetics Director and CEO, Dean Burns, walks through relevant topics including:Manufacturing of the Ocumetics IOLJourney to first-in-human studyQ&A sessionThanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in the future!https://youtu.be/4zxDK3kSSYE?si=omXiuekk30ZBqHgn